CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
lapatinib and Vinorelbinedrug
Likely dose
lapatinib and Vinorelbine 1250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01128543
NCT01128543Phase 2Completed
CompareCT.gov

A Multicenter, Open-Label, Phase II Study of Lapatinib in Combination With Vinorelbine in Subjects With ErbB2 Amplified Recurrent and Metastatic Breast Cancer

GlaxoSmithKline·interventional·Posted May 24, 2010·Updated Dec 12, 2012

In Brief

A Phase 2 clinical trial evaluating lapatinib and Vinorelbine for Cancer. Completed, enrolled 29 participants across 8 sites.

Detailed Summary

This is a Multicenter, Open-Label, Phase II Study of lapatinib in Combination with Vinorelbine in women with documented evidence of HER2/neu positive breast cancer which is metastatic or recurrent and with or without prior chemotherapy or anti-HER2/neu targeted therapy in the metastatic and relaps setting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesTurkey (Türkiye)
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 24, 2010
Enrollment StartApr 1, 2009
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.1 years ago

Interventions

lapatinib and Vinorelbinedrug

Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.